- Home
- KLRA vs GHRS Comparison
KLRA vs GHRS Comparison
Compare KLRA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRA | GHRS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KLRA | GHRS |
|---|---|---|
| Price | $14.84 | $27.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | ★ 719.9K | 228.4K |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.15 | $11.83 |
| 52 Week High | $23.82 | $31.44 |
Technical Indicators
Market Signals| Indicator | KLRA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 45.17 |
| Support Level | N/A | $26.32 |
| Resistance Level | $19.02 | $28.96 |
| Average True Range (ATR) | 1.27 | 1.08 |
| MACD | -0.12 | -0.18 |
| Stochastic Oscillator | 4.65 | 29.84 |
Price Performance
Historical ComparisonAbout KLRA Kailera Therapeutics Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.